What the FDA labels say about taking them together
Docetaxel and hyaluronidase/pertuzumab/trastuzumab
Hyaluronidase/pertuzumab/trastuzumab's FDA label of May 21, 2026 names docetaxel in its warnings and precautions section; the docetaxel labels PlainMeds reads (4) do not name hyaluronidase/pertuzumab/trastuzumab. The hyaluronidase/pertuzumab/trastuzumab label: “An increased incidence of LVEF decline has been observed in patients treated with intravenous pertuzumab, intravenous trastuzumab, and docetaxel.”
Check it at the source: the docetaxel FDA label on DailyMed (effective July 15, 2025, Avyxa Pharma, LLC); the hyaluronidase/pertuzumab/trastuzumab FDA label on DailyMed (effective May 21, 2026).
What does the docetaxel label say about hyaluronidase/pertuzumab/trastuzumab?
Docetaxel's label (effective July 15, 2025) and its 3 other brand-application labels do not name hyaluronidase/pertuzumab/trastuzumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (DOCIVYX), Avyxa Pharma, LLC, effective July 15, 2025 (SPL set 4763744e-360e-4d37-be05-cce4114548cd), via openFDA; the full label on DailyMed
What does the hyaluronidase/pertuzumab/trastuzumab label say about docetaxel?
Hyaluronidase/pertuzumab/trastuzumab label, warnings and precautionsAn increased incidence of LVEF decline has been observed in patients treated with intravenous pertuzumab, intravenous trastuzumab, and docetaxel.
Source: FDA drug label (Phesgo), Genentech, Inc., effective May 21, 2026 (SPL set 27dd5e6b-72cd-458d-a015-cf4dab5800da), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Docetaxel | Hyaluronidase/pertuzumab/trastuzumab | |
|---|---|---|
| Labeled for | Breast cancer, Lung cancer, Prostate cancer | Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once